Ant0i-invasion drugs

Breast Cancer Research and Treatment

Volumn 38, Issue 1, 1996, Pages 121-132

  Dickson, R B ^a   Johnson, M D ^a   Maemura, M ^a   Low, J ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Angiogenesis; Invasion; Metastasis; Motility; New drugs

Indexed keywords

BATIMASTAT; BRYOSTATIN 1; CICAPROST; CYTOSTATIC AGENT; CYTOTOXIC AGENT; FUMAGILLOL CHLOROACETYLCARBAMATE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CANCER MORTALITY; CONFERENCE PAPER; METASTASIS; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0030071607     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01803790     Document Type: Article

References (127)

1. Drake JW: Mutation rates. Bioessays 2:137-140, 1992
2. Cohen SM, Ellwein LB: Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 51:6493-6505, 1991
3. Tlsty TD, White A, Sanchez J: Suppression of gene amplification in human cell hybrids. Science 256: 1425-1427, 1992
4. Thompson AM, Steel CM, Chetty U: p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer 61:74-78, 1990
5. Davidoff AM, Kerns BJM, Pence JC: p53 alterations in all stages of breast cancer. J Surg Oncol 48:260-267, 1991
6. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa APM, Chiba I, Takahashi T, Nau MM, Callahan R, Minna JD: Mutations in the p53 gene in primary human breast cancers. Cancer Res 51:6194-6198, 1991
7. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS: Association of low nm23 RNA levels in human primary infiltrating ductal carcinomas with lymph node involvement and other histopathologic indicators of high metastatic potential. Cancer Res 49:5185-5190, 1989
8. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038, 1993
9. Counter CM, Hirte HW, Bacchetti S: Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 91:2900-2904, 1994
10. Moffett BF, Baban D, Bao L, et al: Fate of clonal lineages during neoplasia and metastasis studied with an incorporated genetic marker. Cancer Res 52:1737-1743, 1992
11. Sato T, Akiyama F, Sakamoto G: Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res 51:5794-5799, 1991
12. Borg A: Gene alterations in human breast cancer. In: Spandidos DA (ed) Current Perspectives on Molecular and Cellular Oncology. JAI Press, Greenwich CT, 1992, pp 21-79
13. Ciardiello F, Gottardis M, Basolo F, Pepe S, Normanno N, Dickson RB, Bianco AR, Salomon DS: Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor α genes in in vitro transformation of human mammary epithelial cells. Molecular Carcinogenesis 6:43-52, 1992
14. Valverius EM, Ciardiello F, Heldin NE, Blondel B, Merlo G, Smith G, Stampfer MR, Lippman ME, Dickson RB, Salomon DS: Stromal influences on transformation of human mammary epithelial cells overexpressing c-myc and SV40T. J Cell Physiol 145: 207-216, 1990
15. Dati C, Muraca R, Tazartes O: c-erbB-2 and ras expression levels in breast cancer are correlated and show a cooperative association with unfavorable clinical outcome. Int J Cancer 47:833-838, 1991
16. Barbareschi M, Leonardi E, Muuri FA, et al: p53 and erbB2 protein expression in breast carcinomas: an immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98: 408-418, 1992
17. Amundadottir LT, Johnson MD, Smith G, Merlino GT, Dickson RB: Interaction of transforming growth factor α and c-myc in mouse mammary gland tumorigenesis. Keystone Conference on Breast and Prostate Cancer II, 1994 (Abstract)
18. Sinn E, Muller W, Pattengale P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic actions of oncogenes in vivo. Cell 49:465-475, 1987
19. Rusty AK, Dyson N, Bernards R: Amino terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product. Nature 352: 541-544, 1991
20. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336, 1991
21. Boyer B, Tucker GC, Thiery JP, Boyer B: Alternative patterns of mitogenesis and cell scattering induced by acidic FGF and a function of cell density in a rat bladder carcinoma cell line. Cell Regulation 1:975-988, 1990
22. Strange R, Li F, Friis RR, Reichmann E, Haenni B, Burri PH: Mammary epithelial differentiation in vitro: minimum requirements for a functional response to hormonal stimulation. Cell Growth Different 2:549-559, 1991
23. Sommers CL, Thompson EW, Torri JA, Kemler R, Gelmann EP, Byers SW: Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Different 2:365-372, 1991
24. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR, Dickson RB: Association of increased basement membrane-invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150:534-544, 1992
25. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, Cano A: Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 142:987-993, 1993
26. Navarro P, Gomez M, Pizarro A, Gamallo C, Quintanilia M, Cano A: A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis. J Cell Biol 115 2:517-533, 1991
27. Goldberg GI, Eisen AZ: Extracellular matrix metalloproteinase in tumor invasion and metastases. In. Lippman ME, Dickson RB (eds) Regulatory Mechanisms in Breast Cancer. Kluwer, Boston, 1990, pp 421-440
28. Rochefort H, Augereau P, Capony F, Garcia M, Cavailles V, Freiss G, Morisset M, Vignon F: The 52k cathepsin D of breast cancer: structure, regulation, function, and clinical value. In: Lippman ME, Dickson RB (eds) Breast Cancer: Cellular and Molecular Biology. Kluwer, Boston, 1988, pp 207-222
29. Sloan BF: Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol 1:137-152, 1990
30. Kane SE, Gottesman MM: The role of cathepsin L in malignant transformation. Semin Cancer Biol 1:127-136, 1990
31. Johnson MD, Torri JA, Lippman ME, Dickson RB: The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 53:873-877, 1993.
32. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90:5021-5025, 1993
33. Stack MS, Gray RD, Pizzo SV: Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain. Cancer Res 53:1998-2004, 1993
34. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65, 1994
35. Xu D, Emoto N, Glaid A, Slaughter C, Kan S, deWitt D, et al: ECE-1: a membrane-bound metalloprotease that catalogues the proteolytic activation of big endothelium-1. Cell 80:473-480, 1994
36. Freije JMP, Dicz-Hza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, et al: Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinoma. J Biol Chem 24:16766-16785, 1994
37. Fazioli F, Blasi F: Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends in Pharm Sci 15:25-29, 1994
38. Zou Z, Anisowicz A, Hendrix MC, Thor A, Neveu M, Sheng S, Rafidi K, Sefton E, Sager R: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263:526-529, 1994
39. Stetler-Stevenson WG, Liotta LA, Brown PD: Role of type IV collagenases in human breast cancer. In: Dickson RB, Lippman ME (eds) Genes, Oncogenes and Hormones. Kluwer, Boston, 1992, pp 21-42
40. Uría JA, Ferrando AA, Velasco G, Freije JMP, López-Otín C: Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 54:2091-2094, 1994
41. Albini A, Melchiori A, Santa L, Liotta LA, Brown PD, Stetler-Stevenson WG: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83:775-779, 1991
42. DeClerck YA, Yean TD, Chan D, Shimada H, Langley KE, Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52:701-708, 1992
43. Tsuchiya Y, Sato H, Endo Y, Okada Y, Mai M, Sasaki T, Seiki M: Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res 53:1397-1402, 1993
44. Melchiori A, Albini A, Ray JM, Stetler-Stevenson WG: Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix of metalloproteinase enzyme prosegment. Cancer Res 52:2353-2356, 1992
45. Galardy RE, Grobelny D, Foellmer HG, Fernandez LA: Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide. Cancer Res 54:4715-4718, 1994
46. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53:2087-2091, 1993
47. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54:4726-4728, 1994
48. Taraboletti G, Belotti D, Garofolo A, Drudis T, Borsotti P, Brown PD, Giavazzi R: Anti-angiogenic potential of a synthetic inhibitor of metalloproteinases, batimastat (BB-94), and inhibition of vascular tumor growth. Clin Exp Metastasis 12:78, 1994 (Abstract)
49. Brown PD: Preclinical and clinical studies on the matrix metalloproteinase inhibitor, batimastat (BB-94). Clin Exp Metastasis 12:23, 1994 (Abstract)
50. Wojtowicz S, Ness E, Dickson RB, Low J, Barter J, Sale M, McCann P, Hawkins M: Pharmacokinetics of Batimastat (BB-94): A novel matrix metalloproteinase inhibitor (MMP1) administered intraperitoneally. Proc ASCO 14:474, 1995 (Abstract)
51. Boyer B, Tucker GC, Valles AM, Franke WW, Thiery JP: Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells. J Cell Biol 109:1495-1509, 1989
52. Lee SA, Karaszkiewicz JW, Anderson WB: Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Res 52:3750-3759, 1992
53. O'Brian CA, Vogel VG, Singletary SE, Ward NE: Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49:3215-3217, 1989
54. Hartwig JH, Thelen M, Rosen A, Janmey PA, Nairn AC, Aderem A: MARCKS is an actin filament cross-linking protein regulated by protein kinase C and calcium-calmodulin. Nature 356:618-620, 1992
55. Isakov N, Gopas J, Priel E, Segal S, Altman A: Effect of protein kinase C activating tumor promoters on metastasis formation by fibrosarcoma cells. Invasion Metast 11:14-24, 1991
56. Eck SL, Perkins ND, Carr DP, Nabel GJ: Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-κB in vivo. Mol Cell Biol 13:6530-6536, 1993
57. Johnson MD, Torri J, Lippman ME, Dickson RB: Regulation of the invasiveness of the human breast cancer cell line MCF-7 by agents that act through protein kinase C. Proc Keystone Symposium on Breast and Prostate Cancer II, Lake Tahoe, 1994
58. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Critical Reviews in Oral Biology and Medicine 4(2):197-250, 1993
59. Isakov N, Gopas J, Priel E, Segal S, Altman A: Effect of protein kinase C-activating tumor promoters on metastasis formation by fibrosarcoma cells. Invasion Metast 11:14-24, 1991
60. Reuning U, Wilhelm O, Schmitt M, Graeff H: Phosphorothioate antisense oligodeoxynucleotides targeting transcription factor NF-KB suppress urokinase secretion in human ovarian carcinoma cells without altering plasminogen activator type-1 production. Clin Exp Metastasis 12:20-21, 1994 (Abstract)
61. 1 promoter by antagonizing AP-1 activity. Mol Endocrinol 7:1347-1356, 1993
62. Johnson MD, Torri J, Lippman ME, Dickson RB: The invasiveness of MCF-7 human breast cancer cells is regulated by agents that act through protein kinase C. Proc Fifth International Meeting of the Metastasis Research Society, Washington DC, 1994 (Abstract)
63. Dumont JA, Jones Jr WD, Bitonti AJ: Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C. Cancer Res 52:1195-1200, 1992
64. Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD: Successful treatment of murine melanoma with bryostatin-1. Cancer Res 51:682-687, 1991
65. Hornung RL, Pearson JW, Beckwith M, Longo DL: Preclinical evaluation of hryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101-107, 1992
66. O'Brian CA, Ward NE: Biology of the protein kinase C family. Cancer Metast Rev 8:199-214, 1989
67. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR: A Phase I study of intravenous bryostatin-1 in patients with advanced cancer. Br J Cancer 68:418-424, 1993
68. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett N, Talbot DC, Ganesan T, Pettit GR, Balkwill F, Harris AL: Phase I study of bryostatin-1: assessment of interleukin 6 and tumor necrosis factor a induction in vivo. J Natl Cancer Inst 85:1812-1818, 1993
69. Dumont JA, Jones WD Jr, Bitonti AJ: Inhibition of experimental metastasis and cell adhesion of B16F1 melanoma cells by inhibitors of protein kinase C. Cancer Res 52:1195-1200, 1992
70. Hornung RL, Pearson JW, Beckwith M, Longo DL. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101-107, 1992
71. Kennedy MJ, Prestigiacomo LJ, Tyler G, May WS, Davidson NE: Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 52:1278-1283, 1992
72. Dickson RB, Johnson MD, Maemura M, Low J: Anti-invasion drugs. Proc New Approaches in the Therapy of Breast Cancer, Washington DC, 1994 (Abstract)
73. Streuli CH, Bailey N, Bissell MJ: Control of mammary epithelial differentiation: basement membrane induces tissue-specific gene expression in the absence of cell-cell interaction and morphological polarity. J Cell Biol 115:1383-1395, 1991
74. Martignone S, Menard S, Bufalino R, Cascinelli N, Pellegrini R, Tagliabue E, Andreola S, Rilke F, Colnaghi MI: Prognostic significance of the 67-kilodalton laminin receptor expression in human breast cancer carcinomas. J Natl Cancer Inst 85:200-206, 1993
75. Castronova V, Taraboletti G, Liotta LA, Sobel ME: Modulation of laminin receptor expression by estrogen and progestins in human breast cancer. J Natl Cancer Inst 81:781-787, 1989
76. Shi YE, Lippman ME, Torri J, Yieh L, Sobel ME, Yamada Y, Dickson RB, Thompson EW: Expression of the 67kDa laminin receptor in human breast cancer cells: regulation by progestins. J Clin Exp Met 11: 251-262, 1993
77. Schwartz MA, Ingber DT: Integrating with integrins. Mol Biol Cell 5:389-393, 1994
78. Hynes RO: Integrins: a family of cell surface receptors. Cell 48:549-554, 1987
79. Weiner TM, Liu ET, Craven RJ, Cance WG: Expression of focal adhesion kinase gene and invasive cancer. Lancet 342:1024-1025, 1993
80. Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME, Dickson RB: ICI 164,384: a pure anti-estrogen for basement membrane invasiveness and proliferation of MCF-7 cells. Cancer Res 49:6929-6934, 1989
81. Schor SL, Greg MA, Ellis I, Schor AM, Howell A, Sloan P, Murphy R: Petal-like fibroblasts: Their production of migration-stimulating factor and role in tumor progression. In: Dickson RB, Lippman ME (eds) Mammary Tumorigenesis and Malignant Progression. Kluwer, Boston, 1994, pp 277-298
82. Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME: Growth factor mRNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 51:4978-4985, 1992
83. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C: Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123:223-235, 1993
84. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Lamacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348:699-704, 1990
85. Sakakura T, Ishihara A, Yatani R: Tenascin in mammary gland development: from embryogenesis to carcinogenesis. In: Lippman ME, Dickson RB (eds) Regulatory Mechanisms in Breast Cancer. Kluwer, Boston, 1991, pp 365-382
86. McCormick BA, Zetter BR: Adhesive interactions in angiogenesis and metastasis. Pharmac Ther 53:239-260, 1992
87. Davies BR, Barraclough R, Rudland PS: Induction of metastatic ability in a stably diploid benign rat mammary epithelial cell line by transfection with DNA from human malignant breast carcinoma cell lines. Cancer Res 54:2785-2793, 1994
88. Valles AM, Tucker GC, Thiery JP, Boyer B: Alternative patterns of mitogenesis and cell scattering induced by acidic FGF as a function of cell density in a rat bladder carcinoma cell line. Cell Regulat 1:975-988, 1990
89. Jouanneau J, Gavrilovic J, Caruelle D, Jaye M, Moens G, Caruelle JP, Thiery JP: Secreted or nonsecreted forms of acidic fibroblast growth factor produced by transfected epithelial cells influence cell morphology, motility, and invasive potential. Proc Natl Acad Sci USA 88:2893-2897, 1991
90. Rosen EM, Knesel J, Goldberg ID: Scatter factor and its relationship to hepatocyte growth factor and met. Cell Growth Different 2:603-607, 1991
91. Raz A: Autocrine motility factor receptor and invasion. Clin Exp Metastasis 12:11-12, 1994 (Abstract)
92. Liotta LA, Murata J, Cluir T, Lee MY, Arestad A, Stracke ML: cDNA cloning of the autocrine cell motility factor autotaxin (ATX). Clin Exp Metastasis 12:3-4,68, 1994
93. Schneider MR, Schirner M: Antimetastatic prostacyclin analogs. Drugs Fut 18:29-48, 1993
94. Schirner M, Schneider MR: The prostacyclin analogue cicaprost inhibits metastasis of tumours of R3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma. J Cancer Res Clin Oncol 118: 497-501, 1992
95. Liu B, Timar J, Howleth J, et al: Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C. Cell Regulation 2:1045-1055, 1991
96. Hown KV, Nelson KK, Renaud C, et al: Fatty acid modulation of tumor cell adhesion to microvessel endothelium and experimental metastasis. Prostaglandins 44:413-429, 1992
97. Liu B, Renaud C, Nelson KK, et al: Protein kinase C inhibitor calphostin C reduces B16 amelanotic melanoma cell adhesion to endothelium and lung colonization. Int J Cancer 49:109-113, 1991
98. Liu B, Maher RJ, Hannun YA, Porter AT, Honn KV: 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKCa. J Natl Cancer Inst 86: 1045-1051, 1994
99. Gould KJ, Polokoff MA, Friedman PA, Huany TF, Holt JC, Cook JJ, Niewiarowski S: Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med 195:168-171, 1990
100. Williams JA: Disintegrins: RGD-containing proteins which inhibit cell/matrix interactions (adhesion) and cell/cell interactions (aggregation) via the integrin receptors. Pathol Biol 40:813-821, 1992
101. 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res 54: 4993-4998, 1994
102. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267:10931-10934, 1992
103. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NPH, Risau W, Ullrich A: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogcncsis and angiogenesis. Cell 72:835-846, 1993
104. Kim I, Manni A, Lynch J, Hammond JM: Identification and regulation of insulin-like growth factor binding proteins produced by hormone-dependent and -independent human breast cancer cell lines. Mol Cell Endocrinol 78:71-78, 1991
105. Thorpe PE, Derbyshire EJ, Andrade SP, Press N, Knowles PP, King S, Watson GJ, Yang Y-C, Rao-Betté M: Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res 53:3000-3007, 1993
106. Wellstein A, Zugmaier G, Calitano J, Kern F, Paik S, Lippman ME: Pentosanpolysulfate inhibits Kaposi-FGF induced tumor growth. J Natl Cancer Inst 83: 716-720, 1991
107. Abe J, Zhou W, Takuwa N, Kurokawa K, Kumada M, Takuwa Y: A fumagillin derivative angiogenesis inhibitor, AGX-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 54:3407-3412, 1994
108. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res 53:4262-4267, 1993
109. Welch DR, Harper DE, Yohem KH: U-77,863: a novel cinnanamide isolated from Streptomyces griseoluteus that inhibits cancer invasion and metastasis. Clin Exp Met 11:201-212, 1993
110. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53:1833-1837, 1993
111. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704, 1992
112. Blood CH, Zetter BR: Tumor interactions with the vasculature: angiogenesis and tumor metastases. Biochem Biophys Acta 1032:89-118, 1990
113. Weidner N, Semple JP, Welsch WR, Folkman JR: Tumor angiogenesis and metastases - correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
114. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
115. Fox SB, Gatter KC, Bicknell R, Going JJ, Stanton P, Cooke TG, Harris AL: Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 53:4161-4163, 1993
116. Fisher B, Gunduz N, Coyle J, Rudock C, Suffer E: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 49:1996-2001, 1989
117. Price JE, Polyzos A, Zhang RD, Daniels LM: Tumorigenicity and metastases of human breast carcinoma cell lines in nude mice. Cancer Res 50:717-721, 1990
118. Meschter CL, Connolly JM, Rose DP: Influence of regional location of the inoculation site and dietary fat on the pathology of MDA-MB-435 human breast cancer cell-derived tumors grown in nude mice. Clin Exp Metastasis 10:167-173, 1992
119. Noguchi M, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I, Mizukami Y: Effects of switching from a high fat diet to a low fat diet on tumor proliferation and cell kinetics of DMBA-induced mammary carcinoma in rats. Oncology 49:246-252, 1992
120. Nakanishi H, Taylor RM, Hawkins AL, Griffin CA, Martin GR, Parsaniti A: Establishment of hormone-dependent and hormone-independent carcinoma cell lines with different metastatic potentials from spontaneous mammary tumors in aged Wistar rats. Int J Cancer 58:592-601, 1994
121. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095-1104, 1991
122. Murakami A, Tanaka H, Matsuzawa A: Association of hst gene expression with metastatic phenotype in mouse mammary tumor cells. Cell Growth Different 1:225-231, 1990
123. Schuuring E, Verhoven E, Mooi WJ, Michalides RJAM: Identification and cloning of two over-expressed genes U 21B31/PRAD 1 and ems-1 within the amplified chromosome 11q13 region in human carcinomas. Oncogene 7:355-361, 1992
124. McLeskey SW, Kurebayashi J, Honig SF, Zwiebel J, Lippman ME, Dickson RB, Kern FG: Development of an estrogen-independent, antiestrogen resistant, metastatic breast carcinoma line by transfection of MCF-7 cells with fibroblast growth factor-4. Cancer Res 53:2168-2177, 1993
125. Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB, Kern FG: Spontaneous metastasis of MCF-7 human breast cancer cell line cotransfected with fibroblast growth factor-4 and bacterial lacZ genes. Cancer Res 53: 2178-2187, 1993
126. Zhang L, Kharbanda S, Chen D, Ding IYF, Kern FG: MCF-7 breast carcinoma cells transfected with an expression vector for fibroblast growth factor 1 arc tumorigenic and metastatic in ovariectomized or tamoxifen-treated nude mice. Proc AACR 35:44, 1994 (Abstract)
127. Wellstein A, Fang W, Khatri A, Lu Y, Swain S, Dickson RB, Susse R, Riegel AT, Lippman ME: A heparin-binding growth factor secreted from breast cancer cells is homologous to a developmentally regulated cytokine. J Biol Chem 267:2582-2588, 1992